Biofrontera AG (BFAGY)

OTCMKTS: BFAGY · Delayed Price · USD
2.20
0.00 (0.00%)
May 24, 2022 12:00 AM EDT - Market closed
Market Cap62.39M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out28.36M
EPS (ttm)0.57
PE Ratio3.89
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Close2.20
Day's Rangen/a
52-Week Range1.50 - 2.78
Beta1.54
AnalystsBuy
Price Target10.60 (+381.8%)
Earnings Daten/a

About BFAGY

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its...

IndustryBiotechnology
IPO DateFeb 14, 2018
CEOHermann Luebbert
Employees95
Stock ExchangeOTCMKTS
Ticker SymbolBFAGY
Full Company Profile

Financial Performance

In 2020, Biofrontera AG's revenue was 30.35 million, a decrease of -2.94% compared to the previous year's 31.27 million. Losses were -13.02 million, 77.0% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 5 analysts, the average rating for BFAGY stock is "Buy." The 12-month stock price forecast is 10.6, which is an increase of 381.82% from the latest price.

Price Target
$10.6
(381.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Biofrontera Stock Is Surging Today

Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany. Th...

1 month ago - Benzinga

Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs

Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its America...

3 months ago - GlobeNewsWire

Why Are Biofrontera Shares Rising Today?

Biofrontera Inc BFRI has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED ...

3 months ago - Benzinga

What's Going On With Biofrontera Shares Today?

Biofrontera Inc (NASDAQ:BFRI) is trading higher Tuesday on abnormally-high volume. The stock is seeing increased interest across social media platforms.

5 months ago - Benzinga

BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today

Biofrontera (BFRI) stock is on the move today as traders take to Twitter (TWTR) to discuss the latest news surrounding the company. The post BFRI Stock Alert: The Social Media Chatter That Has Biofronte...

5 months ago - InvestorPlace

Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage

Benchmark initiated coverage of Biofrontera Inc (NASDAQ:BFRI) with a Buy rating and $11 price target.  The Company specializes in medical dermatology, which recently came public in the U.S. as a carve-o...

5 months ago - Benzinga

Biofrontera Is Promising, But Could Be Limited by Competition and Volatility

BFRI stock could rise on the company's treatment for actinic keratosis, which can lead to skin cancer, but it has hurdles to overcome first. The post Biofrontera Is Promising, But Could Be Limited by Co...

5 months ago - InvestorPlace

$20 Price Prediction Is Ambitious but Possible for Biofrontera

BFRI stock is an imperfect investment as Biofrontera isn't currently profitable, but a new patent could provide a significant revenue source. The post $20 Price Prediction Is Ambitious but Possible for ...

5 months ago - InvestorPlace

Why Are Biofrontera Shares Surging Today?

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Inc (NASDAQ: BFRI) titled "Illumination for Photodynamic Therapy." The patent covers pain-reducing ...

5 months ago - Benzinga

BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Today

Biofrontera (BFRI) stock is getting a boost on Thursday thanks to an update from the United States Patent and Trademark Office. The post BFRI Stock: The News That Has Biofrontera Shares Bounding Higher ...

5 months ago - InvestorPlace

BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $20 Price Prediction

Biofrontera (BFRI) stock is catching the eyes of investors on Wednesday following a bullish price prediction and new rating. The post BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $...

6 months ago - InvestorPlace

Biofrontera AG announces mediation results

Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours an...

6 months ago - GlobeNewsWire

Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021

Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financ...

6 months ago - GlobeNewsWire

Biofrontera AG announces initiation of clinical studies

Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinic...

6 months ago - GlobeNewsWire

Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021

Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its fin...

6 months ago - GlobeNewsWire

Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp

Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the appro...

7 months ago - GlobeNewsWire

Biofrontera reports preliminary approximate revenues for the month of September 2021

Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...

7 months ago - GlobeNewsWire

Biofrontera reports preliminary revenue for the month of August 2021

Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prelimina...

8 months ago - GlobeNewsWire

Biofrontera reports financial results for the six months ended June 30, 2021

Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financ...

9 months ago - GlobeNewsWire

Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021

Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its fin...

9 months ago - GlobeNewsWire

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland

Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klin...

10 months ago - GlobeNewsWire

Biofrontera Inc. seeks IPO in the USA

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc.

10 months ago - GlobeNewsWire

Biofrontera reports preliminary revenue for the month of June 2021

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...

10 months ago - GlobeNewsWire

Biofrontera reports preliminary revenue for the month of May 2021

Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...

11 months ago - GlobeNewsWire

Biofrontera reports Q1 2021 financial results

Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financi...

1 year ago - GlobeNewsWire